Evidence map›Paper›PMID 38407766›Full record

ArticleBiochemical genetics2025

Characterizing Homozygous Variants in Bardet-Biedl Syndrome-Associated Genes Within Iranian Families: Unveiling a Founder Variant in BBS2, c.471G>A.

Masoumeh Heidari Feizabadi, Masoome Alerasool, Atieh Eslahi, Emran Esmaeilzadeh, Mohammad Yahya Vahidi Mehrjardi, Mitra Saket, Shima Farokhi, Zohreh Fattahi, Hamid Reza Khorram Khorshid, Majid Mojarrad

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Masoumeh Heidari FeizabadiGenetics Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-7612-688X
Masoome AlerasoolGenetic Foundation of Khorasan Razavi, Mashhad, Iran.ORCID https://orcid.org/0000-0002-1982-8428
Atieh EslahiFaculty of Medicine, Department of Medical Genetics, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0002-6934-4851
Emran EsmaeilzadehFetal Health Research Center, Hope Generation Foundation, Tehran, Iran.ORCID https://orcid.org/0000-0002-4519-8298
Mohammad Yahya Vahidi MehrjardiDiabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID https://orcid.org/0000-0003-0535-1590
Mitra SaketRP Eye Patients Supporting Institute, Tehran, Iran.ORCID https://orcid.org/0009-0005-4306-7015
Shima FarokhiFaculty of Medicine, Department of Medical Genetics, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0001-8873-9931
Zohreh FattahiGenetics Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-4632-621X
Hamid Reza Khorram KhorshidGenetics Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-0368-9715
Majid MojarradFaculty of Medicine, Department of Medical Genetics, Mashhad University of Medical Sciences, Mashhad, Iran. mojaradm@mums.ac.ir.ORCID https://orcid.org/0000-0001-8742-2844
Mashhad University of Medical Sciences · IRUniversity of Social Welfare and Rehabilitation Sciences · IRShahid Sadoughi University of Medical Sciences and Health Services · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bardet-Biedl syndrome (BBS) is a rare inherited ciliopathy disorder characterized by a broad spectrum of clinical symptoms such as retinal dystrophy, obesity, polydactyly, genitourinary and kidney anomalies, learning disability, and hypogonadism. The understanding of the variants involved in BBS-causing genes remains incomplete, highlighting the need for further research to develop a molecular diagnostic strategy for this syndrome. Singleton whole-exome sequencing (WES) was performed on sixteen patients. Our study revealed (1) nine patients carried eight homozygous pathogenic variants with four of them being novel (2) Specifically, a synonymous splicing variant (c.471G > A) in BBS2 gene in six patients with Baloch ethnicity. The identification of runs of homozygosity (ROH) calling was performed using the BCFtools/RoH software on WES data of patients harboring c.471G > A variant. The presence of shared homozygous regions containing the identified variant was confirmed in these patients. In-silico analysis predicted the effect of the c.471G > A variants on BBS2 mRNA splicing. This variant results in disrupted wild-type donor site and intron retention in the mature mRNA. (3) And a deletion of exons 14 to 17 in the BBS1 gene was identified in one patient by Copy-Number Variation (CNV) analysis using the ExomeDepth pipeline. Our results identified the founder variant c.471G > A in the BBS2 gene in the Baloch ethnicity of the Iranian population. This finding can guide the diagnostic approach of this syndrome in future studies.

Indexed as

Bardet-Biedl SyndromeFounder EffectHomozygoteAdolescentAdultChildExome SequencingFemaleHumansIranMaleMutationPedigreeProteinsRNA SplicingBbs2 protein, humanProteinsBardet–Biedl syndromeFounder variant, Copy-number variationRuns of homozygosity callingWhole exome sequencing

Identifiers

PMID38407766
OpenAlexW4392167458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.